Organogenesis Q2 net revenue falls 58% to $42.8 million; net loss $96.3 million
Organogenesis reported second-quarter 2026 net product revenue of $42.8 million, down 58% from $100.8 million a year earlier, and a net loss of $96.3 million, or $(0.77) per share, compared with a net loss of $9.4 million, or $(0.10) per share, in the second quarter of 2025. The company also lowered its full-year 2026 total net revenue outlook to $179.0 million to $215.0 million, a decline of 62% to 68% from 2025, with management saying the pace of recovery is slower than it expected.
Key points
- Net product revenue of $42.8 million, down 58% from $100.8 million; Advanced Wound Care fell 61% to $36.1 million
- Net loss of $96.3 million, or $(0.77) per share, including income tax expense of $45.4 million
- FY2026 total net revenue guidance of $179.0 million to $215.0 million, a 62% to 68% decline from $564.2 million in 2025; prior guidance assumed a 45% to 52% decline
- Cash, cash equivalents and restricted cash of $46.8 million at June 30, 2026, with no outstanding debt obligations
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.